A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen.
about
Interrogating differences in expression of targeted gene sets to predict breast cancer outcome.MicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis.Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status.Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells.An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors.Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting.Clinical outcomes linked to expression of gene subsets for protein hormones and their cognate receptors from LCM-procured breast carcinoma cells.ErbB4 as a potential molecular target in the treatment of esophageal squamous cell cancers.Bcl-2 promotes metastasis through the epithelial-to-mesenchymal transition in the BCap37 medullary breast cancer cell line.Low serum gastrin associated with ER breast cancer development via inactivation of CCKBR/ERK/P65 signaling
P2860
Q31122465-64573C4C-B8B2-4497-8E73-51C1CC9EDB63Q33618363-34AD21FB-96D7-4770-8AAE-0F64C617BFDBQ34660130-D913FD99-7336-4FA6-9D7A-39DC3F4E18F8Q36466583-CD3A6CB4-D5B1-4368-82A6-CB3AA5D99EEEQ37691657-E003EF0B-DCF8-43E9-8BFC-BAFF94D03F04Q38563530-BE5FC2E4-7307-4454-91AC-DD934FC9D8C1Q41135362-3FBBA03E-59A5-4680-A00A-70128120852CQ51321099-0A321F9F-755D-4006-A1EA-A2F87CFE6147Q54300172-93A3C457-95E8-4316-B01A-3BF05C940418Q55241008-BA10DF25-18B1-4CCF-8BA0-857856CBD6C6Q58774122-18F12DEE-DFE0-4075-A634-77873DFB7E41
P2860
A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A five-gene model predicts cli ...... eated with adjuvant tamoxifen.
@en
A five-gene model predicts cli ...... eated with adjuvant tamoxifen.
@nl
type
label
A five-gene model predicts cli ...... eated with adjuvant tamoxifen.
@en
A five-gene model predicts cli ...... eated with adjuvant tamoxifen.
@nl
prefLabel
A five-gene model predicts cli ...... eated with adjuvant tamoxifen.
@en
A five-gene model predicts cli ...... eated with adjuvant tamoxifen.
@nl
P2860
P1433
P1476
A five-gene model predicts cli ...... eated with adjuvant tamoxifen.
@en
P2093
Daniel Alan Kerr
James L Wittliff
P2860
P2888
P304
P356
10.1007/S12672-011-0080-8
P577
2011-10-01T00:00:00Z